Argent BioPharma (ASX:RGT) Refocuses on Immune Modulation as Licensing Reshapes Its Portfolio

Aditi Sarkar

23 October 2026 09:54 PM AEDT

Argent BioPharma (ASX:RGT) Refocuses on Immune Modulation as Licensing Reshapes Its Portfolio

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Argent concentrated internal development on immune modulation and inflammatory disease.
The company added licensed antiviral commercialisation rights alongside CimetrA.
Its CannEpil framework provided USD 5.5 million of consideration through note forgiveness.
The developer secured additional working-capital loans after September-end.

Argent BioPharma (ASX:RGT) develops, manufactures and licenses therapeutics, with an increasing focus on immune modulation. Its September 2026 quarterly report, released on 23 October, included developments through the announcement date. The update connected a narrower internal research strategy with external commercialisation rights and CannEpil licensing, while the cash flow statement showed continued reliance on financing for working capital.

Internal Development Narrows Its Focus

Following quarter-end, the company refined its strategy around immune modulation and inflammatory disease. RGT-CA91980 became the lead internally developed program, building on the development history of CimetrA and ArtemiC.

The preclinical NanoBodies program remained part of the portfolio, supported by a US provisional patent application. The company was also evaluating research into chronic inflammation, inflammaging and healthy-ageing biology.

The announcement expressly did not present CimetrA as an anti-ageing medicine. Commercialisation, licensing support and a more concentrated development program were separate elements of the strategy, rather than claims of established efficacy across new indications.

Antiviral Rights Add a Commercial Platform

During the quarter, Argent entered a royalty-bearing licence covering antiviral applications associated with Tollovir, Tollovid and NutraVir, together with specified formulations, data, trade secrets and know-how.

The territory was worldwide excluding China, with existing US Tollovid rights preserved and a specified clinical-trial formulation excluded. Substantially all existing NutraVir inventory was to be acquired for USD 1.

The underlying intellectual property and improvements remained with the licensor. Argent received commercialisation rights, while pharmaceutical development would require separate rights and regulatory approvals. Commercial costs were to be shared with the CimetrA strategy.

Royalties Carry Product-Specific Thresholds

Each licensed antiviral product carried royalties of 12% on the first USD 2.5 million of cumulative net sales, 9% on the next USD 2.5 million and 6% thereafter.

Those rates applied separately to Tollovir, Tollovid and NutraVir. They described payments linked to sales under the commercialisation licence rather than an upfront acquisition of the underlying technology.

Alongside this incoming licence, the CannEpil transaction framework granted a partner exclusive global commercialisation rights. Its USD 5.5 million upfront consideration was being satisfied through forgiveness of convertible notes, removing the principal secured liability rather than delivering the same amount as new cash.

CannEpil Expands into Veterinary Development

Argent retained CannEpil intellectual property and manufacturing responsibilities. The human therapeutic royalty remained 15% of net revenues, with manufacturing on a cost-plus basis allowing a margin of up to 20%.

A subsequent addendum extended the licensed field to veterinary applications and introduced a 10% perpetual veterinary royalty. Development initially targeted cancer-related pain in companion animals, beginning with canine oncology.

A US investigational new animal drug file was established on 26 August 2026. The report explicitly distinguished that regulatory step from approval, conditional approval, confirmation of safety or efficacy, or authorisation to market the product in the United States.

Working Capital Remains a Funding Priority

Operating activities used AUD 734,000 during the quarter. Customer receipts were AUD 10,000, while staff costs totalled AUD 149,000, research and development AUD 48,000, and administration and corporate payments AUD 507,000.

The company received AUD 600,000 through its convertible securities financing arrangement. Cash nevertheless closed September at AUD 11,000, compared with AUD 141,000 at the start of the quarter.

After quarter-end, unsecured loan facilities totalling USD 500,000 were entered on 1 October to support working capital. Commercial execution, regulatory progress and access to funding therefore remained distinct requirements alongside the revised portfolio strategy.

FAQs

Q: Was the CannEpil upfront consideration a new cash receipt?

A: It was being satisfied through convertible-note forgiveness, rather than a USD 5.5 million cash payment.

Q: Did the veterinary investigational file permit US marketing?

A: No. The report expressly stated that the file did not constitute approval or marketing authorisation.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.